Key Takeaways
- Amgen increased its 2026 non-GAAP earnings per share (EPS) guidance range to $22.30-$23.50, up from a previous range of $19.80-$22.00.
- $AMGN shares advanced 3.4% to $321.50 in pre-market trading following the announcement.
- The updated outlook reflects strong product performance and pipeline confidence, signaling potential for sustained growth for investors.
- The company also raised its 2026 revenue projection to between $38.2 billion and $39.4 billion from an earlier estimate of $37.0 billion to $39.0 billion.
- A planned CFO transition from Peter Griffith to Michael Lohr, effective early 2025, aligns with the company's long-term strategic financial planning.
Amgen Bolsters 2026 Outlook Amidst Leadership Transition
Amgen Inc. on Tuesday significantly raised its financial guidance for 2026, projecting non-GAAP earnings per share (EPS) of $22.30 to $23.50 and revenue between $38.2 billion and $39.4 billion. This revised outlook, representing a substantial increase from previous estimates, underscores the biotechnology giant's confidence in its product portfolio, pipeline, and operational efficiencies as it navigates a planned Chief Financial Officer transition. The previous non-GAAP EPS guidance was $19.80-$22.00, and revenue was $37.0 billion-$39.0 billion.
The positive financial update immediately resonated with investors, driving $AMGN shares up by 3.4% to $321.50 in pre-market trading. This surge reflects a strong market endorsement of Amgen's growth trajectory and its ability to execute on strategic initiatives, even as it prepares for a key leadership change in its finance department. The announcement also detailed that Executive Vice President and CFO Peter Griffith will retire in early 2025, with Michael Lohr slated to assume the role.
Market Impact
Amgen's stock opened at $319.80, a 2.9% jump from its previous close of $310.75, and traded as high as $322.15 during early Tuesday sessions. The volume of $AMGN shares traded in the first hour exceeded 2.5 million, significantly higher than its 30-day average of 1.7 million shares, indicating robust investor interest and buying pressure. This move added approximately $5.4 billion to Amgen's market capitalization, pushing it above $175 billion.
The upward revision marks a pivotal moment for Amgen, which has been strategically investing in its oncology, inflammation, and rare disease franchises. This performance contrasts with the broader S&P 500 Biotechnology Index ($XBI), which saw a modest 0.8% gain on the same day, highlighting Amgen's outperformance within its sector. The last time $AMGN experienced such a significant single-day pre-market jump on guidance news was in early 2023, following strong Q4 2022 results. The positive sentiment could also spill over to other large-cap biotech firms, potentially boosting the $IBB ETF, as investors may view this as a sign of underlying strength in the broader biopharmaceutical industry's revenue growth prospects.
What Analysts Are Saying
Industry analysts were largely positive on Amgen's updated guidance, viewing it as a clear signal of momentum across its key product lines and pipeline. "According to Guggenheim Securities, Amgen's raised 2026 targets demonstrate an accelerating contribution from newer growth drivers like Repatha and Lumakras, alongside biosimilar expansion," noted a research report distributed to clients Tuesday morning. The firm also highlighted the potential for continued operational leverage to drive EPS growth beyond revenue increases.
Morgan Stanley analysts echoed this sentiment, stating, "The enhanced revenue and EPS projections for 2026 reflect a strong execution track record and confidence in the late-stage pipeline, particularly in oncology and inflammation." They further emphasized that the CFO transition, while significant, appears well-managed and planned, with Michael Lohr's internal promotion ensuring continuity and strategic alignment. However, some analysts, including those at Leerink Partners, suggested that while the guidance raise is positive, it might still incorporate some conservatism regarding the impact of upcoming biosimilar competition for key drugs like Stelara, posing a potential headwind beyond 2026 that investors should monitor.
What to Watch
Investors should closely monitor several factors following Amgen's updated guidance and impending CFO transition. The company's upcoming second-quarter earnings call in late July will provide further granular detail on the performance drivers behind the revised 2026 outlook, including specific revenue contributions from key products like Repatha, Evenity, and Lumakras. Any updates on the timeline and progress of its late-stage clinical trials, particularly for oncology assets like tarlatamab and blinatumomab, will be critical catalysts for future growth.
The transition of the CFO role in early 2025 will also be a key event, with investors watching for any shifts in capital allocation strategy, M&A appetite, or financial reporting under Michael Lohr's leadership. Traders should observe the technical resistance level for $AMGN around $325, a price point not consistently breached since last year, which could signal further upside momentum if overcome. Conversely, strong support is anticipated near the $310 level. Furthermore, any changes in the regulatory landscape, particularly regarding drug pricing legislation or intellectual property protections, could introduce risks that might temper the company's long-term growth projections.
